1. Researchers call out Gilead over diversity of remdesivir trials — Bristol-Myers commits $300M to combat racial disparities — Goldman predicts at least one coronavirus vaccine approval before the end of 2020 — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Blue Belt Technologies

Anonymous board for Blue Belt Technologies


Sort By:
Title
Replies Views
Last Message ↑
  1. Anonymous
    Replies:
    1
    Views:
    3,102
  2. Anonymous
    Replies:
    1
    Views:
    4,048
  3. Anonymous
    Replies:
    5
    Views:
    4,258
  4. Anonymous
    Replies:
    0
    Views:
    2,709
  5. Anonymous
    Replies:
    2
    Views:
    3,033
  6. Anonymous
    Replies:
    2
    Views:
    3,253
  7. Anonymous
    Replies:
    1
    Views:
    2,555
  8. Anonymous
    Replies:
    0
    Views:
    2,645
  9. Anonymous
    Replies:
    3
    Views:
    3,574
  10. Anonymous
    Replies:
    6
    Views:
    3,808
  11. Anonymous
    Replies:
    3
    Views:
    3,341
  12. Anonymous
    Replies:
    0
    Views:
    2,854
  13. Anonymous
    Replies:
    0
    Views:
    2,614
  14. Anonymous
    Replies:
    0
    Views:
    2,963
  15. dspinerep
    Replies:
    1
    Views:
    3,955
  16. Anonymous
    Replies:
    0
    Views:
    3,971
  17. Anonymous
    Replies:
    4
    Views:
    4,822
  18. Anonymous
    Replies:
    4
    Views:
    6,783
  19. Anonymous
    Replies:
    0
    Views:
    4,496
  20. Anonymous
    Replies:
    1
    Views:
    7,926

Thread Display Options

Loading...